NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immuron Limited American Depositary Shares (IMRN) Stock Analysis

Immuron Limited American Depositary Shares (IMRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMRN

$0.97

−$0.05 (−4.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMRN with… →

IMRN Key Statistics

As of Oct 21, 2026
Trading
Open
$0.99
Previous Close
$1.02
Day's Range
0.96–1.00
52-Week Range
0.68–2.25
Volume
12.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.47
Valuation
Market Cap
$7.83M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.34
Financials (FY)
Revenue (FY)
$7.29M+48.63%
Net Income (FY)
−$5.22M
Profit marginThe share of revenue left as profit after all costs and taxes.
−47.71%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.07M
1-Year Return
−57.17%
Dividend and dates
Avg Volume
2.06M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMRN closed at $0.97, −57.17% over 1 year.

Immuron Limited American Depositary Shares (IMRN) has a market capitalization of $7.83M.

In fiscal 2025, IMRN reported revenue of $7.29M.

IMRN Stock Return by Calendar Year

Immuron Limited American Depositary Shares (IMRN) return since Jun 2017: what $10,000 became

1 year
$10,000 $4,283
−57.17%
5 years
$10,000 $2,687
−73.13%
Since Jun 2017
$10,000 $1,161
−88.39%

If you had invested $10,000 in Immuron Limited American Depositary Shares (IMRN) at the close on June 9, 2017, the earliest close on record here, it would have been worth $1,161 at the close on October 21, 2026: −88.39% in total, −20.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+27.13%
2025−55.12%
2024−9.33%
2023−9.86%
2022−16.80%
2021−60.75%
2020+75.48%
2019−37.41%
2018+9.64%
2017 (partial year)−36.68%

As of October 21, 2026.

IMRN Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$7.29M−$5.22M−71.6%
2024$4.90M−$6.94M−141.5%
2023$1.80M−$3.79M−209.8%
2022$765.19K−$2.85M−373.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.29M$4.77M−$5.36M−$5.22M−71.6%
2024$4.90M$3.34M−$5.22M−$6.94M−141.5%
2023$1.80M$1.31M−$3.41M−$3.79M−209.8%
2022$765.19K$523.50K−$3.12M−$2.85M−373.0%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

IMRN Valuation vs Biotechnology Median

Median of 608 stocks
MetricIMRNBiotechnology medianvs median
P/S ratio1.0113.300.1x the median
Profit margin−47.71%−38.31%9.4 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Immuron Limited American Depositary Shares (IMRN) at $7.83M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 7 employees.

Over the past 52 weeks the price has ranged from $0.68 to $2.25. IMRN last closed at $0.97 on October 21, 2026. That is −$0.05 (−4.90%) against the previous close. The latest close sits 43.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.29M. Against the prior fiscal year total of $4.90M, that is a change of +48.63%. The same year closed with a net loss of $5.22M. Profit margin runs at −47.71%. That is 9.4 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.34.

Across the 4 fiscal years on file, revenue moves from $765.19K in 2022 to $7.29M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.01 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −57.17%. Measured over 5 years, that is −23.11% a year compounded. The reported beta is 0.47. Daily returns over the trailing 9 years annualize to a volatility of 305.53%.

Growth & Income

No dividend is on file for IMRN.

So far in 2026 the total return is +27.13%. Across the complete calendar years on file, 2020 returned +75.48% and 2021 returned −60.75%. Of the 8 complete calendar years on file, 2 finished higher.

Peer Comparison

Immuron Limited American Depositary Shares (IMRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immuron Limited American Depositary Shares IMRN $7.83M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immuron Limited American Depositary Shares has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immuron Limited American Depositary Shares

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Visit website →